Eagle Asset Management Inc. lifted its holdings in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) by 0.3% in the third quarter, HoldingsChannel reports. The firm owned 984,335 shares of the company’s stock after buying an additional 2,939 shares during the quarter. Eagle Asset Management Inc.’s holdings in Biohaven Pharmaceutical were worth $41,066,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Nisa Investment Advisors LLC grew its holdings in shares of Biohaven Pharmaceutical by 511.1% in the third quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock valued at $46,000 after purchasing an additional 920 shares in the last quarter. Tower Research Capital LLC TRC acquired a new position in shares of Biohaven Pharmaceutical in the second quarter valued at approximately $65,000. Aperio Group LLC acquired a new position in shares of Biohaven Pharmaceutical in the second quarter valued at approximately $71,000. Glen Harbor Capital Management LLC grew its holdings in Biohaven Pharmaceutical by 165.9% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock worth $76,000 after acquiring an additional 1,088 shares in the last quarter. Finally, Canton Hathaway LLC acquired a new position in Biohaven Pharmaceutical during the 3rd quarter worth approximately $83,000. Hedge funds and other institutional investors own 90.74% of the company’s stock.

Several research analysts have commented on the stock. Canaccord Genuity set a $80.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a report on Monday, August 26th. Oppenheimer set a $67.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a report on Wednesday, October 9th. Morgan Stanley set a $50.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “hold” rating in a report on Friday, August 9th. Zacks Investment Research cut shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a report on Monday, October 21st. Finally, Cantor Fitzgerald boosted their price target on shares of Biohaven Pharmaceutical from $87.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, October 28th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $69.82.

NYSE BHVN opened at $48.33 on Friday. The stock has a market capitalization of $2.45 billion, a PE ratio of -7.86 and a beta of 0.34. Biohaven Pharmaceutical Holding Co Ltd has a 52 week low of $29.17 and a 52 week high of $67.86. The firm has a 50 day moving average of $44.64 and a two-hundred day moving average of $48.09.

Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings data on Friday, November 1st. The company reported ($2.04) earnings per share for the quarter, missing the consensus estimate of ($1.57) by ($0.47). Sell-side analysts predict that Biohaven Pharmaceutical Holding Co Ltd will post -7.68 earnings per share for the current year.

In related news, Director Gregory Bailey acquired 5,000 shares of Biohaven Pharmaceutical stock in a transaction dated Tuesday, August 20th. The stock was acquired at an average price of $37.65 per share, for a total transaction of $188,250.00. Following the transaction, the director now owns 2,587,601 shares of the company’s stock, valued at $97,423,177.65. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Elyse Stock sold 800 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $45.01, for a total transaction of $36,008.00. Following the sale, the insider now owns 800 shares of the company’s stock, valued at approximately $36,008. The disclosure for this sale can be found here. Insiders have sold a total of 28,500 shares of company stock valued at $1,283,747 in the last 90 days. Insiders own 23.90% of the company’s stock.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Story: Short Selling

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.